이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Samsung Bioepis to launch second biosimilar by June
- Collected
- 2016.04.02
- Distributed
- 2016.04.04
- Source
- Go Direct
The reimbursement price for biosimilar Renflexis (infliximab) has been notified, said MSD Korea on Friday, the local marketing partner of Samsung Bioepis. Renflexis, the second biosimilar product from Samsung Bioepis, is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease in adults. Its reference drug is Janssen’s Remicade. The biosimilar was approved last December.
Renflexis will be reimbursed at 363,530 won, 5 percent cheaper than Janssen’s Remicade (383,051 won), but the same as Celltrion’s Remsima, a peer biosimilar.
Samsung Bioepis founded in February 2012 received approval for its first biosimilar product Brenzys (etanercept) from the Ministry of Food and Drug Safety last September. The drug was first prescribed to patients last December in Korea. Brenzys was also approved by the European Medicines Agency (EMA) in January and began to be marketed in Norway and the U.K. later.
The price is set at an economical level compared with the reference drug to offer various treatment options to patients, said MSD Korea responsible for selling and marketing Renflexis in Korea. The new product will be officially launched in June.
By Lee Dong-in
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]